Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.43 |
| ▸ | ECE1 | P42892 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | WNT3A | P56704 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2900631 | 1.00 | F10 (0.43) | F10ECE1NPC1RAB9AMAOB | |
| SCHEMBL2895796 | 0.92 | TRPV1 (0.43) | F10ECE1NPC1RAB9AMAOB | |
| SCHEMBL2895016 | 0.90 | F10 (0.42) | F10ECE1NPC1RAB9AMAOB | |
| SCHEMBL2895761 | 0.89 | F10 (0.43) | F10ECE1NPC1RAB9AMAOB | |
| SCHEMBL2893134 | 0.89 | KCNQ3 (0.49) | F10ECE1NPC1RAB9AMAOB | |
| SCHEMBL2894989 | 0.89 | KCNQ3 (0.47) | F10ECE1NPC1RAB9AMAOB | |
| SCHEMBL2898989 | 0.88 | ECE1 (0.43) | F10ECE1NPC1RAB9AMAOB | |
| SCHEMBL2891751 | 0.88 | KCNQ3 (0.48) | F10ECE1NPC1RAB9AMAOB | |
| SCHEMBL4406277 | 0.87 | RAB9A (0.55) | NPC1RAB9ADGAT1 | |
| Hydrochloric Acid SCHEMBL2899132 | 0.86 | RAB9A (0.55) | NPC1RAB9ADGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586573-B2 | N-(Aminoheteroaryl)-1H-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof | SANOFI (FR) | 2013-11-19 | — | — | US | disclosed |
| US-20100286119-A1 | N-(Aminoheteroaryl)-1H-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2010-11-11 | — | — | US | disclosed |
| US-7786104-B2 | N-(aminoheteroaryl)-1H-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2010-08-31 | — | — | US | disclosed |
| EP-2049525-B1 | N-(AMINOHETEROARYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, AND PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI AVENTIS (FR) | 2009-12-30 | — | — | EP | disclosed |
| US-20090156573-A1 | N-(Aminoheteroaryl)-1H-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286119-A1 | N-(Aminoheteroaryl)-1H-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof | IDO1, IDO2, TPH1 | F10 1568/4885ECE1 1214/4885NPC1 997/4885 |
| US-20090156573-A1 | N-(Aminoheteroaryl)-1H-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof | IDO1, IDO2, TPH1 | F10 1568/4885ECE1 1214/4885NPC1 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.